Schizophrenia is a serious and chronic mental disorder, in which both genetic and environmental factors have a role in the development of the disease. Neuregulin-1 (NRG1) is one of the most established genetic risk factors for schizophrenia, and disruption of NRG1 signaling has been reported in this disorder. We reported previously that NRG1/ErbB4 signaling is inhibited by receptor phosphotyrosine phosphatase-b/f (RPTP b/f) and that the gene encoding RPTPb/f (PTPRZ1) is genetically associated with schizophrenia. In this study, we examined the expression of RPTPb/f in the brains of patients with schizophrenia and observed increased expression of this gene. We developed mice overexpressing RPTPb/f (PTPRZ1-transgenic mice), which showed reduced NRG1 signaling, and molecular and cellular changes implicated in the pathogenesis of schizophrenia, including altered glutamatergic, GABAergic and dopaminergic activity, as well as delayed oligodendrocyte development. Behavioral analyses also demonstrated schizophrenia-like changes in the PTPRZ1-transgenic mice, including reduced sensory motor gating, hyperactivity and working memory deficits. Our results indicate that enhanced RPTPb/f signaling can contribute to schizophrenia phenotypes, and support both construct and face validity for PTPRZ1-transgenic mice as a model for multiple schizophrenia phenotypes. Furthermore, our results implicate RPTPb/f as a therapeutic target in schizophrenia.
Introduction
Schizophrenia (MIM 181500) is a serious and chronic mental disorder with a 1% lifetime prevalence, characterized by positive symptoms (that is, delusions and hallucinations), negative symptoms (that is, social withdrawal, anhedonia, and blunted affect) and cognitive dysfunction (that is, deficits in attention, working memory and executive function). [1] [2] [3] Population, family and twin studies indicate that schizophrenia is highly heritable, with additional non-genetic factors involved in the disease. 4, 5 On the basis of pharmacological and postmortem brain studies, it has been argued that altered neuronal signaling and circuitry, including the glutamatergic, 6 -8 dopaminergic [9] [10] [11] and GABAergic pathways, 12, 13 as well as white matter abnormalities, 14, 15 have important roles in the development of the disease, however, detailed molecular and cellular mechanism underlying schizophrenia pathogenesis are still unknown.
Several lines of evidence indicate that abnormalities in neuregulin-1 (NRG1) signaling, mediated via the ErbB receptor family, are involved in schizophrenia. Genetic association of the gene encoding NRG1 (NRG1) with schizophrenia is one of the most well-replicated findings in genetic dissection of schizophrenia. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] NRG1 is a multifunctional protein that has important roles in development of central nervous system, 26 and it has been shown that NRG1 þ /À mice demonstrate several molecular changes resembling abnormalities observed in schizophrenia, such as altered glutamatergic, 27 ,28 dopaminergic 29 and GABAergic signaling, [30] [31] [32] [33] [34] as well as altered oligodendrocyte and myelin 35, 36 development. 29, [37] [38] [39] These mice have also shown abnormal behaviors relevant to schizophrenia. 19, 33 Altered expression of NRG1 mRNA in the postmortem brain of schizophrenia has been reported [40] [41] [42] and recent finding using cultured lymphocytes suggest that NRG1 signaling is suppressed in patients with schizophrenia. 43, 44 There is also emerging data implicating ERBB4 in schizophrenia. Genetic association of ERBB4 20, 35 and gene-gene interaction between ERBB4 and NRG1 in schizophrenia 20, 36 and relevant cognitive dysfunction have been reported. [45] [46] [47] In addition, altered expression of ERBB4 in brain tissue from patients with schizophrenia has been observed. 48 Finally, ErbB4 þ /À and transgenic mice harboring dominant negative form of ErbB4 showed molecular and behavioral changes relevant to schizophrenia.
We previously reported that a central nervous systemspecific phosphatase, receptor phosphotyrosine phosphatase-b/z (RPTPb/z) is complexed with ErbB4 via MAGI scaffolding proteins, such that NRG1/ErbB4 signaling is negatively regulated by RPTPb/z in vitro. We also found that the PTPRZ1 gene, which encodes RPTPb/z, is genetically associated with schizophrenia. 49 Recent copy number variation analyses have identified deletions in genes coding for ErbB4 and MAGI2 50 in schizophrenia. On the basis of these results, we hypothesized that increased expression of RPTPb/z would inhibit NRG1 signaling in vivo, thus, leading to schizophrenia phenotypes. To directly test this idea, we examined the expression levels of RPTPb/z in the brains of patients with schizophrenia, and developed and characterized a mouse overexpressing RPTPb/z. To generate the mouse we used a bacterial artificial chromosome (BAC) transgenic approach that has robust and stable expression, with expression regulated under the control of human cis elements, and hence closest to the native state.
Materials and methods
Postmortem human brain specimens. Total RNA from dorsolateral prefrontal cortex of 105 samples was provided by the Stanley Foundation (35 each for schizophrenia, bipolar disorder and healthy controls). The three diagnostic groups were matched by age, sex, race, postmortem interval (PMI), pH, side of brain, mRNA quality, smoking status and lifetime antipsychotics dose. Detailed demographic information is available (http://www.stanleyresearch.org/dnn/Portals/0/ Stanley/Array%20Collection%20Demographic%20Details% 20Chart-Final.pdf). cDNA was synthesized using the highcapacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA). Primers for short and long form of RPTPb and four endogenous controls (ACTB, GAPD, GUSB and PPIA) were designed using the software provided for the Universal Probe Library system (Roche Applied Science; https://www.roche-applied-science.com/sis/rtpcr/upl/ acenter.jsp). Analysis of variance (ANOVA) with Tukey's post hoc tests was used for group comparison.
Mice. All animal procedures were approved by the Institutional Animal Care and Use Committee of Mount Sinai School of Medicine and the James J Peters Veterans Affairs Medical Center. Human BAC RP11-367M11, containing the entire PTPRZ1 gene was introduced to C57BL/6xC3H F1 hybrid mice and the allele was maintained on a C57Bl6 background. The BAC is 180 kb in length and with flanking genomic sequences of 110 and 42 kB around the PTPRZ1 gene. The human gene codes for a protein that shares 85% identity and 82% similarity with the mouse gene product.
In situ hybridization. In situ hybridization was performed using digoxygenin-labeled cRNA probes, with sequence corresponding to 5228-5746 bp of mouse cDNA for RPTPb/z (NM_001081306). Sense and antisense probes were synthesized and digoxygenin-labeled by in vitro transcription using Sp6 and T7 RNA polymerase (Roche, Basel, Switzerland). In situ hybridization was performed using IsHyb in situ hybridization kit (BioChain, Hayward, CA, USA) on 20-mm thick sagittal cryosections, according to the manufacturer's protocol.
NRG1 stimulation in hippocampal slices. A NRG1 stimulation assay was performed as previously described. 51 Hippocampi were dissected and 200-mm thick slices were prepared using a tissue chopper (Vibratome, Bannockburn, IL, USA). Slices were incubated with 200 ng ml À1 of recombinant human neuregulin (NRG1-beta EGF domain, R&D systems, Minneapolis, MN, USA) or vehicle in ice-cold Krebs-Ringer solution containing 118 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 25mM NaHCO 3 , 10 mM glucose supplemented with complete protease EDTA-free inhibitor tablets (Roche Applied Science, Penzberg, Germany) and protein phosphatase inhibitor set (Millipore, Temecula, CA, USA) (pH 7.4) with aeration. After 20 min of stimulation, ice-cold EGTA was added to terminate the reaction. Tissue was then homogenized in lysis buffer (150 mM NaCl, 20 mM Tris-HCl, 10% glycerol, 5 mM EDTA and 1% NP-40) supplemented with protease and phosphatase inhibitors, and separated on 10% SDS-PAGE gels. Phosphorylation of extracellular signal-regulated kinase (ERK) was normalized to ERK levels. ANOVA with Tukey's post hoc tests was used for group comparisons.
Quantitative PCR assays. Total RNA was isolated and cDNA was prepared using the high-capacity cDNA archive kit (Applied Biosystems). The mRNA levels of the target genes were measured by qPCR using the Roche Universal Probe Library system (Roche Applied Science, Indianapolis, IN, USA). Four endogenous control genes (Ppia, Actb, Gusb and B2m) were also analyzed for reference. The ABI Prism 7900 sequence detection system (Applied Biosystems) was used for the PCR reaction. Relative expression levels for control sample were calculated with qBase software (http://medgen. ugent.be/qbase/). 52 Unpaired t-tests were used for group comparisons.
Western blotting. Western blotting was performed according to standard protocols. The antibodies and their concentration used were as follows: RPTPb (mouse monoclonal; 1:250; Molecular Probes, Eugene, OR, USA), phosophotyrosine-ERK (SC-7383; mouse monoclonal, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), ERK (SC-1647; mouse monoclonal, 1:1000, Santa Cruz Biotechnology), NR2B (rabbit polyclonal; 1:1000; R&D Systems), phospho-NR2B (rabbit polyclonal; 1:1000; R&D Systems), GSK3b (mouse monoclonal, 1:2000, Transduction Laboratories, Franklin Lakes, NJ, USA), GSK3b phosphorylated at Ser9 (rabbit polyclonal, 1:1000, Cell Signaling, Danvers, MA, USA).
Electrophysiology. Sections were prepared as described above and electrophysiology was carried out as we have recently described. 53, 54 In brief, individual slices were placed in a submerged recording chamber and were perfused with recording solution at a rate of 1-2 ml min
À1
. Schaffer collateral-commissural fibers were stimulated every 20 s. Stimulus intensity was adjusted to evoke 30-40% maximal stimulation, and the initial slopes of field excitatory Cruz Biotechnology for PV, Alexa Fluor 488 goat anti-mouse for CC1/APC, Alexa Fluor 555 donkey anti-rabbit for NG2, both 1:10 000, Invitrogen, Carlsbad, CA, USA). 4',6-Diamidino-2-phenylindole (1:1000; Molecular Probes) was used as a nuclear counterstain. Parvalbumin-positive cells were counted using Zeiss Axiovision2 (Zeiss, Oberkochen, Germany) and Stereo investigator software (MBF Bioscience, Williston, VT, USA). A minimum of four sections per mouse and three mice were evaluated for the quantification. Student's t-tests were used for comparisons. Confocal images of NG2 and CC1/APC-positive cells were obtained using a Zeiss LSM 510 Meta confocal laserscanning microscope (Zeiss). Optical sections of confocal epifluorescence images were sequentially acquired with LSM5 Image Browser software (Zeiss). Immunoreactive cells for NG2 and CC1/APC were counted with the ImageJ cell counting plug-in (http://rsbweb.nih.gov/ij/). A minimum of three sections per mouse and three mice were evaluated for the quantification. w 2 -tests were used for group comparisons.
High-performance liquid chromatography. Dopamine, homovanillic acid and 3,4-dihydroxyphenylacetic acid levels were measured as previously described, 55 using an isocratic high-performance liquid chromatography system with electrochemical detection, consisting of a pump (ESA model 582, ESA, Chelmsford, MA, USA), automatic injector (ESA model 542 autosampler) and a Coulochem III detector (ESA) in conjunction with a guard cell (ESA model 5020) and an analytical cell (ESA model 5014B). Cell potentials were set at 350, 150 and 220 mV for the guard, E1 and E2 cells, respectively. A volume of 25 ml per sample was injected with a flow rate of 0.6 ml min
, and passed through a 150-mm column (ESA model MD-150X3.2) with a particle size of 3 mm and pore size of 12 nm. The mobile phase consisted of 10% acetonitrile, 90 mM NaH 2 PO 4 , 1.7 mM 1-octane sulfonic acid, 50 mM citric acid and 50 mM EDTA, pH 3. Data were collected and analyzed using the EZStart software (Agilent Technologies, Santa Clara, CA, USA). Standards were run in parallel. Unpaired t-tests were used for group comparisons.
Behavioral analyses. Three cohorts of transgenic mice and wild-type littermate controls were studied. Each cohort contained 20 transgenic mice and 20 wild-type animals (10 males and 10 females for each genotype). Behavioral testing was performed in the Mouse and Rat Phenotyping Shared Research Facility of Mount Sinai School of Medicine located at the James J Peters VA Medical Center, Bronx, NY, USA. Animals were bred at the Mount Sinai School of Medicine and transferred to the Veterinary Medical Unit at the James J Peters VA Medical Center for behavioral testing at 10 weeks of age. After transfer, animals were singly housed and allowed an acclimation period before initiation of testing, which begun at 14-16 weeks of age. All mice were housed in standard clear plastic cages at a constant temperature of 21-22 1C, with rooms kept under 12-h light/ dark cycles with lights switched on at 0700 h. Access to food and water was ad libitum. Animals were housed on racks in random order to prevent rack position effects. Testing was performed by a single investigator blinded to the genotype of the animals.
Open-field test. Open-field testing was performed as previously described. 56 Mice were brought into the experimental room and were allowed to acclimate for 1 h before testing. Each mouse was placed for 30 min in a square openfield box under low lighting conditions. An automated infrared beam array system measured locomotion in the center and periphery of the test arena. Experimentally naive mice were used for all experiments and activity data were collected in 5-min intervals over the 120-min open-field session. Where indicated, MK-801 (0.3 mg kg
) was injected intraperitoneally at 25 min before behavioral testing. Similarly, amphetamine (2 mg kg À1 ) was injected intraperitoneally at 25 min before behavioral testing for five consecutive days. Total distance traveled was analyzed with two-way ANOVA (genotype and treatment) for the study with MK-801. Total distance traveled during the first 40 min was compared by using a three-way ANOVA (genotype, day (repeated measure) and treatment) for the study with amphetamine. Sphericity was assessed using the Mauchly test.
Prepulse inhibition test. Prepulse inhibition was assessed as previously described. 56 Mice were brought into the experimental room and were allowed to acclimate for a minimum of 1 h before testing. Mice were individually placed in a startle enclosure in the startle chamber with a background white noise of 70 dB and were left undisturbed for 10 min. Then a session was started that consisted of 10 trials of each condition (no discrete stimulus, prepulse only, prepulse-pulse and pulse only) presented in a pseudorandomized order. Prepulse-pulse trial started with a 50-ms null period, followed by a 20-ms prepulse white noise of 72 dB. After a 100-ms delay, the startle stimulus was presented (a 40-ms 120 dB white noise), followed by a 290-ms recording time. The total duration of each trial was 500 ms. The formula 100À((startle response on acoustic prepulse þ pulse stimulus trials/pulse stimulus response alone trials) Â 100) was used to calculate percent prepulse inhibition. Unpaired t-tests were used for group comparison.
Light/dark transition test. Light/dark transition testing was performed as previously described. 56 Mice were placed in the dark side of a two-chamber light/dark apparatus and were allowed to move freely between the two chambers with the door kept open for 10 min. The total number of transitions and time spent in each side were recorded. Unpaired t-tests were used for group comparisons.
Social interaction. Social interaction was tested using a three-chamber social interaction and recognition test. 57 The subject was offered a choice between investigating an unfamiliar mouse and a novel object. Interaction time was collected in 5-min segments for each trial. Unpaired t-tests were used for group comparisons.
Eight-arm radial maze test. Working memory was measured by win-shift task using an eight-arm radial maze. 58 Mice were food-restricted to 80-85% of their free-feeding weights. Mice were first habituated to an eight-arm radial maze for 10 days by freely foraging for food rewards located at the end of the maze arms. Training was given during daily trials for 10 days that consisted of two phases. During the first phase, mice were put in the center of the maze and four random arms were opened. The animals then had 5 min to collect all of the food rewards located at the end of the arms. The mice were then removed into a holding chamber for 1 min, and the center and arms of the maze were cleaned with 70% ethanol. During the second phase, the mice were returned to the center of the maze and all eight arms of the maze were opened. However, only the four previously unopened arms contained food reward for which the animals had 5 min to retrieve. During testing, the delay between phases was increased from 1 min to 5, 30 and 60 min on consecutive days. Errors were classified as within-phase (re-entries into target arms) or across-phase (entries into arms baited in the first phase). Data were analyzed for each error type by using two-way repeated measures ANOVA.
Conditional fear conditioning test. For contextual fear conditioning, the conditioning chamber (Coulbourne FreezeFrame system, White Hall, PA, USA) consisted of a metal and plexiglass chamber (7 Â 7 Â 12 00 ) equipped with a grid floor for delivery of the conditioned stimulus and an overhead camera to monitor movement and freezing. The conditioning chamber was placed inside a soundproof isolation cubicle. Training occurred in the dark with background noise generated by a small fan. Each mouse was placed inside the conditioning chamber for 2 min before delivery of a 2 s foot shock (0.6 mA) accompanied by a white house-light. Each mouse remained in the chamber for an additional 60 s after which another foot shock was given. Each mouse was returned to its home cage after another 30 s. Freezing was defined as a lack of movement (except for respiration). Baseline freezing was measured during 0-2 mins of the training day. Contextual fear memory was determined at 24 h after training by measuring freezing during a 3-min test in the conditioning chamber. Unpaired ttests were used for group comparisons.
Statistical analysis. Statistical analyses were performed using SPSS 16.0 (SPSS, Chicago, IL, USA). The results were expressed as mean values ± s.e.m. Statistical significance was set at level of 0.05.
Results
Increased expression of RPTPb/f in schizophrenia. We had previously observed a genetic association of PTPRZ1 with schizophrenia and were interested in assessing whether expression of the gene product RPTPb/z might be altered in schizophrenia as further evidence that it may contribute to pathogenesis. Analysis by qPCR showed increased expression of RPTPb/z in the dorsolateral prefrontal cortex of schizophrenia (Figure 1 ) (ANOVA with Tukey's post hoc tests, Po0.05). Although the samples were matched on these measures, we also carried out multiple regression analysis which showed that possible confounding factors including PMI, brain pH, brain side, smoking status and lifetime antipsychotic dose did not affect expression of RPTPb/z (data not shown).
Generation of PTPRZ1-transgenics. On the basis of the postmortem brain data above, we generated mice overexpressing human RPTPb/z by introducing a BAC, 59 which included the entire human PTPRZ1 gene (RP11-367M1). The PTPRZ1-transgenics were viable and showed Increased expression of PTPRZ1 and schizophrenia N Takahashi et al no obvious alterations in gross brain structure or hippocampal cytoarchitecture. In situ hybridization using a probe that recognizes both human and mouse transcripts of PTPRZ1 demonstrated that expression of PTPRZ1 was increased in the transgenics but the regional distribution pattern was similar between the transgenics and wild-type littermates (Figure 2a) . We also confirmed that BAC transgenesis resulted in B50% increase in expression of both RPTPb/z mRNA and protein (Supplementary Figures  S1a-c) .
Inhibition of NRG1 signaling in PTPRZ1-transgenics. To determine whether increased expression of RPTPb/z led to decreased NRG1 signaling, hippocampal slices were prepared from the PTPRZ1-transgenics and littermate controls and stimulated with NRG1. As we predicted based on our prior in vitro studies, 49 stimulation increased levels of phosphorylated ERK in wild-type mice, but not in transgenic littermates (Figure 2b ) (ANOVA with Tukey's post hoc tests, Po0.001).
Reduced GABA signaling in PTPRZ1-transgenics. One of the most established findings from postmortem brain studies of schizophrenia is the reduced expression of GAD67 in the prefrontal cortex of patients, and this change has been attributable to a reduced number of PV-positive cells in this region. 60, 61 It has also been demonstrated that NRG1/Erbb4 signaling controls the development of inhibitory circuits in the brain, and that reduced signaling suppresses expression of GAD67 in interneurons, 32 providing a mechanistic link between altered NRG1 signaling and reduced GABA signaling in schizophrenia. 21 Interestingly, we found reduced expression of GAD67 in the medial prefrontal cortex of PTPRZ1-transgenic mice, when examined by qPCR (Figure 3a) (unpaired t-test, Po0.05). In addition, we observed that the numbers of PV-positive neurons were significantly reduced in this region of the PTPRZ1-transgenics, as compared with wild-type littermates (Figure 3b ) (unpaired t-test, Po0.05).
Increased dopamine signaling in PTPRZ1-transgenics. We next evaluated dopaminergic activity in PTPRZ1-transgenic mice. Dopamine abnormalities are considered core features of schizophrenia, given the molecular targets of antipsychotics and that elevated dopamine signaling precedes the onset of schizophrenia and can lead to cognitive dysfunction. 62 We found B40% increase in the levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the striatum in the transgenics compared with wild-type littermates (Figure 3c ) (unpaired ttest, Po0.05). Analysis of qPCR showed overexpression of the dopamine D2 receptor in this region (Figure 3d ) (unpaired t-test, Po0.001). These findings are of interest in light of a recent study showing that disruption of NRG1/Erb signaling in oligodendrocytes induces hyperdopaminergia in the striatum. 29 Levels of phosphorylated GSK3b, a key mediator of D2 receptor signaling, were significantly reduced, which could be reversed by clozapine (Supplementary Figures S2a, b) . Amphetamine treatment induces synaptic dopamine release, and can cause psychotic symptoms in healthy controls while exaggerating symptoms in patients with schizophrenia. 63 The PTPRZ1-transgenics showed an increased response to amphetamine, consistent with enhanced dopaminergic activity in these mice (Figure 3e ) (three-way ANOVA (genotype, day (repeated measure) and treatment), Po0.05).
Altered NMDA signaling in PTPRZ1-transgenics. NRG1 also has an important role in glutamatergic neurotransmission, 21 previously implicated in psychosis and schizophrenia in part because non-competitive agonists of the N-methyl-D-aspartate receptors induce psychotic features resembling schizophrenia. 6 One effect of NRG1 signaling is the enhanced phosphorylation of the NR2B subunit, and this phosphorylation is attenuated in heterozygous Nrg1-and Erbb4-deficient mice (Nrg1 þ /À and Erbb4 þ /À) 28 and reduced phosphorylation may contribute to N-methyl-D-aspartate receptor dysfunction in schizophrenia. Phosphorylation of NR2B was significantly reduced in the hippocampus of the PTPRZ1-transgenics Figures S3a, b) . PTPRZ1-transgenics showed increased locomotor activity when challenged with the N-methyl-D-aspartate receptor antagonist MK801 (Figure 4b ) (unpaired t-test, Po0.05), consistent with altered glutamate signaling in these mice.
As intact glutamatergic transmission is necessary for longterm potentiation, we next measured long-term potentiation in these mice and found that long-term potentiation induced by either tetanus or theta-burst stimulation was significantly reduced in the PTPRZ1-transgenic mice (Figure 4c ) (unpaired t-test, Po0.05), similar to what has been reported in Nrg1 þ /À mice. 28 Delayed oligodendrocyte development in PTPRZ1-transgenics. White matter and oligodendrocyte abnormalities have been implicated in schizophrenia 14, 64 and NRG1 has been implicated in myelination. 29 RPTPb/z is expressed in oligodendrocytes, including adult oligo- dendrocyte progenitors, and RPTPb/z activity inhibits the differentiation of these cells. 65 PTPRZ1-trangenics showed a transient reduction in expression of oligodendrocyte-and myelin-related genes up to 3 weeks of age (Figures 4d and e) (unpaired t-test, Po0.05 for CLDN11, CNP1, Mag, Mbp, Mobp and Plp1, Po0.01 for Sox10 at 2 weeks of age; Po0.05 for CLDN11, Mbp, and Mobp, Po0.01 for Sox10 at 3 weeks of age). Immunohistochemical analyses demonstrated a delay in the development of oligodendrocyte lineage cells in the transgenic animals ( Figure 4f ) (w 2 -test, Po0.001).
Schizophrenia-related behavioral alterations in PTPRZ1-transgenics. PTPRZ1-transgenics showed reduced prepulse inhibition of startle (Figure 5a ) (unpaired t-test, Po0.05), reflecting sensory gating abnormalities that are also observed in schizophrenia. 66 Furthermore, prepulseelicited reactivity, considered to be more specific to psychotic symptoms of schizophrenia, 66 was significantly reduced in the transgenics (Figure 5b ) (unpaired t-test, Po0.05). Importantly, the PTPRZ1-transgenics showed impaired working memory-considered to be a core cognitive dysfunction in schizophrenia-as shown by increased WT (20) TG ( 
TG(4)
Frequency ( WT (7) TG ( Increased expression of PTPRZ1 and schizophrenia N Takahashi et al errors in the win-shift task using the eight-arm radial maze test (Figures 5c and d) (two-way repeated measures ANOVA, Po0.05). In addition, the transgenics were impaired in a contextual fear conditioning test, suggesting problems in associative learning and memory (Figure 5e ) (unpaired t-test, Po0.05). Other measures associated with the schizophrenia phenotype were also subtly altered, including increased locomotor activity, reduced social activity and increased anxiety (Supplementary Figures S4a-c) .
Discussion
We observed that RPTPb/z expression is upregulated in schizophrenia. One caveat with our study is that we measured expression of RPTPb/z only in dorsolateral prefrontal cortex because of the limited availability of other tissue, therefore, we cannot conclude that RPTPb/z is overexpressed more broadly; hence, our finding requires replication in an independent cohort and with additional brain regions. Interestingly, since we initiated this study, an additional study has reported increased expression of this gene in the amygdala in independent samples in schizophrenia. 67 We observed increased expression of RPTPb/z could inhibit NRG1 signaling in slices and led to several molecular features that capture aspects of schizophrenia, including reduced GABAergic signaling, enhanced dopamine signaling in the striatum and altered NMDA signaling, as well as behavioral and cognitive changes in mice. Furthermore, we observed delayed oligodendrocyte and myelin development in the PTPRZ1-transgenics, which reflects an additional deficit observed in schizophrenia. Taken together, our results indicate that increased expression of RPTPb/z in vivo captures many key aspects of the molecular, cellular, behavioral and cognitive phenotypes of schizophrenia.
The mechanisms by which PTPRZ1 overexpression leads to these multiple abnormalities are currently unknown but some relationships can be proposed. On the basis of recent studies showing that ErbB4 is predominantly expressed in interneurons in adult mouse brain 32, 33 and that GABAergic dysfunction induced elevated dopaminergic activity, 68, 69 one could speculate that increased expression of RPTPb/z may inhibit ErbB4 function in interneurons leading to subsequent changes, including GABAergic dysfunction and elevated dopaminergic activity.
We also found additional molecular and behavioral changes relevant to glutamatergic signaling in the PTPRZ1-transgenics, however, effects of NRG1 on this pathway have not yet been completely clarified. 70 There is a possibility that these changes in glutamate signaling might be a consequence of direct interaction of RPTPb/z with synaptic proteins such as PSD95 71 and MAGIs 72 rather than via the NRG1 pathway. It has been proposed that insults affecting myelination in early life could induce imbalances in the development of brain circuits relevant to schizophrenia pathogenesis, 73 hence, one can also speculate that delays in oligodendrocyte development in the transgenic animals will have impact on the development of the circuitry underlying glutamateric, GABAergic and/or dopaminergic signaling.
Some postmortem brain studies have suggested that NRG1 signaling is upregulated in schizophrenia. 42, 51, 60 Interestingly, a recent study using transgenic mice, which overexpress NRG1, demonstrated that even though these transgenics showed molecular changes in the opposite direction to the findings from postmortem brain studies of schizophrenia-including increased PV-positive cells, increased expression of oligodendrocyte markers and decreased expression of dopamine synthetic enzymes-they manifested almost the same behavioral phenotypes as Nrg þ / À or ErbB4 þ /À mice. 74 It is therefore possible that for certain critical pathways, over or under activity are equally disruptive and can produce overlapping end results.
Many schizophrenia-relevant phenotypes have been defined in mice ( 75, 76 ; and see Supplementary Table S1 ) and extensive efforts have been made to develop mouse models with face, construct and predictive validity in schizophrenia. We have demonstrated that PTPRZ1-transgenic mice WT (15) TG (18) WT (15) TG ( Fear conditioning test showed reduced freezing time at 24 h after training. WT, wildtype mice; TG, transgenic mice; *Po0.05; ***Po0.001.
Increased expression of PTPRZ1 and schizophrenia N Takahashi et al demonstrate reduced NRG1/Erb signaling, which in turn is associated with many of these schizophrenia phenotypes (Supplementary Table S1 ), making it a potentially useful model for understanding the biology of schizophrenia. The diverse phenotypes affected in the PTPRZ1-transgenic mice indicate that they satisfy face validity for multiple facets of schizophrenia. The genetic association of PTPRZ1 with schizophrenia that we previously reported, and the elevated expression of RPTPb/z in the brain in schizophrenia shown here indicate that the model also has construct validity for schizophrenia. More studies will be needed to assess the degree to which the PTPRZ1-transgenic model has predictive validity, although we are encouraged to see that dopamine signaling abnormalities were reversed by clozapine. The elevated expression of RPTPb/z in the brain in schizophrenia indicates that the development of specific inhibitors of RPTPb/z activity and/or function represents a novel therapeutic approach for schizophrenia.
